Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–67 of 67 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Irritable Bowel Syndrome With Diarrhea Clear all

Conditions: Irritable Bowel Syndrome, Diarrhea
Interventions: Donor Fecal Microbiota Transplantation, Autologous Fecal Microbiota Transplantation; Biological
Lead sponsor: Madhusudan (Madhu) Grover, MBBS; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: IBS (Irritable Bowel Syndrome), Diarrhea
Interventions: MITI-001 administration; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Redwood City, California • Stanford, California

Conditions: Non-Constipation Irritable Bowel Syndrome
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 88
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more

Conditions: Diarrhea-predominant Irritable Bowel Syndrome
Interventions: Serum-derived bovine immunoglobulin protein isolate (SBI); Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 76
States / cities: Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 66 more

Conditions: Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions: Alosetron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 177
States / cities: Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more

Conditions: Irritable Bowel Syndrome
Interventions: Medical Food, Placebo; Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Ulcerative Colitis, Healthy, Irritable Bowel Syndrome With Diarrhea
Interventions: Aquamin; Drug
Lead sponsor: James Varani; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Digestive Disorders, Irritable Bowel Syndrome, Constipation, Diarrhea
Interventions: Not listed
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Irritable Bowel Syndrome
Interventions: 0.075 mg RVX-100, 0.125 mg RVX-100, 0.250 mg RVX-100, placebo; Drug
Lead sponsor: Revogenex, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 257
States / cities: Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more

Conditions: Diarrhoea Predominant Irritable Bowel Syndrome
Interventions: EnteraGam; Other
Lead sponsor: Entera Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Greenwich, Connecticut • Hamdon, Connecticut • Coral Springs, Florida + 13 more

Conditions: Irritable Bowel Syndrome
Interventions: 25mg Eluxadoline, 100mg Eluxadoline; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 6
States / cities: Corona, California • Miami, Florida • Stockbridge, Georgia + 2 more

Conditions: Irritable Bowel Syndrome
Interventions: Dextofisopam; Drug
Lead sponsor: Pharmos; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 79
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Eluxadoline; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions: DNK333, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 180 participants
Timeline: 2006 – 2007
U.S. locations: 37
States / cities: Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions: Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Irritable Bowel Syndrome
Interventions: DNK333; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 29
States / cities: Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more

Conditions: Irritable Bowel Syndrome
Interventions: Olorinab, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more

Search by objective public record fields.

Fecal Microbiota Transplantation for IBS

Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

SBI in Children With d-IBS

GI Permeability Change in Response to Aquamin®

AcuGraph and Digestive Symptoms

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Retrospective Study of IBS-D Patients Previously Receiving SBI

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome

Eluxadoline Bile Acid Malabsorption (BAM) Study

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)